Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ATF4 | P18848 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22628358 | 0.92 | RXFP1 (0.44) | RXFP1ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL22627982 | 0.89 | ATF4 (0.43) | RXFP1ALDH1A1ATF4MEN1KMT2A | |
| SCHEMBL22627670 | 0.89 | ALDH1A1 (0.41) | RXFP1ALDH1A1ATF4MEN1KMT2A | |
| SCHEMBL22628180 | 0.88 | NPC1 (0.46) | RXFP1ALDH1A1ATF4POLB | |
| SCHEMBL22956605 | 0.88 | ATF4 (0.40) | RXFP1ALDH1A1ATF4MEN1KMT2A | |
| SCHEMBL22628192 | 0.86 | ALDH1A1 (0.43) | RXFP1ALDH1A1ATF4MEN1KMT2A | |
| SCHEMBL25804558 | 0.86 | ALDH1A1 (0.42) | RXFP1ALDH1A1ATF4TDP1 | |
| SCHEMBL22627878 | 0.86 | CYP1A2 (0.40) | ALDH1A1ATF4POLB | |
| SCHEMBL22956424 | 0.85 | RXFP1 (0.42) | RXFP1ALDH1A1ATF4MEN1KMT2A | |
| SCHEMBL22627579 | 0.85 | ATF4 (0.42) | RXFP1ALDH1A1ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452456-B1 | BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | RXFP1 2368/4885ALDH1A1 3433/4885ATF4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.